- Home
- VERU vs RLMD Comparison
VERU vs RLMD Comparison
Compare VERU & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- RLMD
- Stock Information
- Founded
- VERU 1971
- RLMD 2004
- Country
- VERU United States
- RLMD United States
- Employees
- VERU N/A
- RLMD N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- RLMD Health Care
- Exchange
- VERU Nasdaq
- RLMD Nasdaq
- Market Cap
- VERU 107.2M
- RLMD 110.6M
- IPO Year
- VERU 1990
- RLMD N/A
- Fundamental
- Price
- VERU $0.58
- RLMD $3.01
- Analyst Decision
- VERU Strong Buy
- RLMD Hold
- Analyst Count
- VERU 4
- RLMD 2
- Target Price
- VERU $4.00
- RLMD $7.50
- AVG Volume (30 Days)
- VERU 996.7K
- RLMD 117.3K
- Earning Date
- VERU 12-06-2024
- RLMD 11-07-2024
- Dividend Yield
- VERU N/A
- RLMD N/A
- EPS Growth
- VERU N/A
- RLMD N/A
- EPS
- VERU N/A
- RLMD N/A
- Revenue
- VERU $14,091,909.00
- RLMD N/A
- Revenue This Year
- VERU N/A
- RLMD N/A
- Revenue Next Year
- VERU N/A
- RLMD N/A
- P/E Ratio
- VERU N/A
- RLMD N/A
- Revenue Growth
- VERU N/A
- RLMD N/A
- 52 Week Low
- VERU $0.36
- RLMD $1.88
- 52 Week High
- VERU $1.92
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- VERU 24.06
- RLMD 31.18
- Support Level
- VERU $0.72
- RLMD $3.06
- Resistance Level
- VERU $0.83
- RLMD $3.43
- Average True Range (ATR)
- VERU 0.06
- RLMD 0.20
- MACD
- VERU -0.02
- RLMD -0.05
- Stochastic Oscillator
- VERU 1.38
- RLMD 6.61
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.